Tue Nov 24, 2009
UCLA Health System Research and Education: David Geffen School of Medicine at UCLAPatient Care: UCLA Health System
UCLA Urology
Home
For Patients
About Us
Appointments
Innovations and Technology
Newsletters
Webcasts - Urology
News and Events
Maps and Directions
Academic Information
SPORE In Prostate Cancer
How You Can Help
Resources and Publications
Contact Us
Sitemap
Intranet



Request an Appointment

Phone: (310) 794-7700

Visiontree optimal care
patient registration

UCLA Urology #4 in the Nation Highest Ranked in California
UCLA Urology
#4 in the Nation
Highest Ranked in California

Increase (+) Default Decrease (-) Font Size

Services / Prostate Cancer - High Intensity Focused Ultrasound

Clinical Trial Information - Prostate Cancer


Prostate Cancer: High Intensity Focused Ultrasound (HIFU) for Recurrent Prostate Cancer

Prostate Cancer: This is a clinical trial for men with recurrent prostate cancer after failed radiation therapy, using the investigational therapy high-intensity focused ultrasound (HIFU).

  • Principal Investigator: Leonard S. Marks, M.D,
  • Co-Investigators: Arie Belldegrun, M.D., Allan Pantuck, M.D.

Objective:

HIFU, or high intensity focused ultrasound, is an exacting technique aiming sound waves at the prostate tissue, rapidly increasing tissue temperature, which destroys the cancerous lesions. To qualify for the clinical trial, participants must have recurrent prostate cancer after treatment with external beam radiation therapy. Initial screening visits will involve physical exams, blood tests and an ultrasound of the prostate.

Common procedural side effects include temporary pain in the area where the HIFU was performed, inability or difficulty with urination, and blood in the urine or semen.

The study is sponsored by Focus Surgery, Inc., manufacturer of the The Sonablate® 500 system, which is the HIFU technology used in the study. Several thousand HIFU procedures have been performed in other countries, but the treatment is currently considered investigational in the United States. The study is part of an FDA-approved clinical trial, which is also approved by the UCLA institutional review board and registered at http://www.clinicaltrials.gov.

Patient Eligibility

To qualify, one must have histologically confirmed, organ confined, adenocarcinoma of the prostate 2 or more years post radiation therapy.

Qualifying participants will receive the outpatient HIFU procedure under anesthesia and follow-up for a year after treatment. All study-related costs, including the HIFU treatment, will be covered by the research study.

For more information

For more information about the study, please call Malu Macairan, research coordinator, at 310-794-3566.